Arvinas ARVN ARV-102 — Program-specific external expense

Similar metrics at other companies

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

KYTXOther Program — External Research And Development Expenses Allocated By Program

$206K-63.1%

RAPPRAP219Program External Expenses — Research And Development Expense

$15.82M+98.7%

ANROALTO-203 — Direct external program expenses:

$6K-99.2%

KYTXKYV One Zero One — External Research And Development Expenses Allocated By Program

$19.01M+22.9%

IDYADarovasertib — External Clinical Development Expenses

$23.33M+1.4%

Questions, answered.

What is Arvinas's ARV-102 — program-specific external expense?

Arvinas (ARVN) reported ARV-102 — program-specific external expense of $5.5M in Q1 2026.

How has Arvinas's ARV-102 — program-specific external expense changed year-over-year?

Arvinas's ARV-102 — program-specific external expense decreased by 15.4% year-over-year, from $6.5M to $5.5M.

What is the long-term trend for Arvinas's ARV-102 — program-specific external expense?

Over 2 years (2023 to 2025), Arvinas's ARV-102 — program-specific external expense has grown at a 202.2% compound annual growth rate (CAGR), from $2.3M to $21M.

What does ARV-102 — program-specific external expense mean?

This metric represents the direct external costs incurred by the company specifically attributable to the development of a particular therapeutic program or product candidate. It captures outsourced research activities, clinical trial site fees, and third-party manufacturing expenses associated with advancing the asset through the pipeline. Monitoring this expense provides insight into the capital intensity and resource allocation required to reach key clinical milestones for a specific drug candidate.